Of note, in the RA-BEAM trial [106], baricitinib was head to head compared with the anti-TNF monoclonal antibody adalimumab, resulting in a significant superiority to adalimumab in ACR20, ACR50 and ACR70 response rate until week 52, and in DAS28-CRP scores, SDAI remission achievement, HAQ-DI scores, and several PROs [112] at week 12. The gene discussed is CRP; the disease is rheumatoid arthritis.